Could a memory drug fight prostate cancer? small trial aims to find out
NCT ID NCT07164794
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether memantine hydrochloride, a drug used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard hormone therapy. Fifteen men with metastatic castration-resistant prostate cancer will take memantine alongside their usual treatment. Researchers will track how long the disease stays under control and whether PSA levels drop.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- memantine hydrochloride
- What this could lead to
- If it works, this could point toward a new way to slow advanced prostate cancer by adding a common Alzheimer's drug to standard care.
- What could go wrong
- This is a very early, small study with only 15 people. It may not show clear benefit, and memantine is not proven for cancer. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?